A placebo-controlled, double-blind, randomised trial of magnesium-pyridoxal-5′-phosphate-glutamate for hypercholesterolaemia and other clinical-chemical risk factors of cardiovascular disease in a primary care setting

European Journal of Clinical Pharmacology

Volumn 56, Issue 12, 2001, Pages 857-863

  Schuitemaker, G E ^a   Van Der Pol, G A ^a   Aretz, C P M ^a   Dinant, G J ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Cardiovascular disease; Hypercholesterolaemia; Magnesium pyridoxal 5 phosphate glutamate

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A; GLUTAMINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PYRIDOXAL 5 PHOSPHATE; PYRIDOXAL PHOSPHATE GLUTAMATE MAGNESIUM;

ADULT; AGED; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; NETHERLANDS; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE;

ADULT; AGED; APOLIPOPROTEINS A; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FEMALE; GLUTAMINE; HUMANS; HYPERCHOLESTEROLEMIA; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; NETHERLANDS; PYRIDOXAL PHOSPHATE; REFERENCE VALUES;

EID: 0034464145     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280000247     Document Type: Article

References (25)

1. Multiple Risk Factor Intervention Trial Group (1982) Multiple risk factor intervention trial: risk factor changes and mortality results. JAMA 248:1465-1477
2. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB (1986) Incidence of coronary heart disease and lipoprotein levels: the Framingham Study. JAMA 256:2835-2838
3. Lipid Research Clinics Program (1984) The lipid research clinics coronary primary intervention trial results. I. Reduction in incidence of coronary heart disease. JAMA 251:351-364
4. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P et al (1987) Helsinki heart study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 317:1237-1245
5. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW et al (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333:1301-1307
6. Simoons ML, Casparie AF (1998) Treatment and prevention of coronary heart diseases by lowering of the serum cholesterol concentration; third consensus 'Cholesterol' (in Dutch). Ned Tijdschr Geneeskd 142:2096-2101
7. Bertolini S, Bon GB, Campbell LM, Farnier M, Langan J, Mahla G et al (1997) Efficacy and safety of atorvastatin compared to pravastatin in patients with hypercholesterolemia. Atherosclerosis 130:191-197
8. Stein E, Sprecher D, Allenby KS, Tosiello RL, Whalen E, Ripa SR (1997) Cerivastatin, a new potent synthetic HMG Co-A reductase inhibitor: effect of 0.2 mg daily in subjects with primary hypercholesterolemia. J Cardiovasc Pharmacol Ther 2:7-16
9. Dallongeville J, Fruchart JC, Pfister P, Bard JM (1994) Fluvastatin reduces levels of plasma and Apo B-containing particles and increases those of LpA-I. European fluvastatin study group. Am J Med 96:32S-36S
10. Fong RL, Ward HJ (1997) The efficacy of lovastatin in lowering cholesterol in African Americans with primary hypercholesterolemia. Am J Med 102:387-391
11. Simons LA (1993) Simvastatin in severe primary hypercholersterolemia: efficacy, safety, and tolerability in 595 patients over 18 weeks. The principal investigators. Clin Cardiol 16:317-322
12. Davidson MH, Nawrocki JW, Weiss SR, Schwartz SL, Lupien PJ, Jones PH et al (1997) Effectiveness of atorvastatin for reducing low-density lipoprotein cholesterol to National Cholesterol Education Prosram treatment goals. Am J Cardiol 80:347-348
13. Kirsten R, Heintz B, Nelson K, Sieberth HG, Oremek G, Hasford J et al (1988) Magnesium pyridoxal 5-phosphate glutamate reduces hyperlipidaemia in patients with chronic renal insufficiency. Eur J Clin Pharmacol 34:133-137
14. Weiser D, Schneider W, Reimann HJ (1992) Effect of magnesium pyridoxal 5-phosphate glutamate in hyperlipidemic patients. Drugs affecting lipid metabolism (abstract). Florence, 13-16 May, p 86
15. 6 derivative", does not affect lipoprotein levels in patients with familial hypercholesterolaemia. Eur J Clin Pharmacol 51:499-503
16. Kögl C, Schneider W, Elstner EF et al (1994) The influence of magnesium pyridoxal-5-phosphate glutamate in comparison with probucol, alpha-tocopherol and trolox on copper-induced oxidation of human low density lipoprotein in vitro. Biochem Pharmacol 47:2201-2206
17. Kostner GM, Schneider W, Weiser D (1992) Effect of magnesium pyridoxal 5-phosphate glutamate on 'lipoxygenase-induced' oxidation of low density lipoproteins. Fourth international symposium on treatment of severe dyslipoproteinemia in the prevention of coronary heart disease. Munich, October 22-23
18. Parvez Z, Speck U (1991) Effect of vitamin B-6 derivatives on blood coagulation and platelet function. J Drug Dev 4:65-69
19. Olbrich HG, Boeker JF, Rachor S, Ketelsen UP, Wieland H, Kober G et al (1992) Effect of magnesium pyridoxal 5-phosphate glutamate on the hamster cardiomyopathy. Drug Res 42:292-296
20. Schneider W (1987) Der hypercholesterinämische und antiatherosklerotische Einfluss von Magnesium-Pyridoxal-5′-Phosphat-Glutamat im Serum, in der Leber und der Aorta hypercholesterolämischer Ratten und Kaninchen. Thesis, Mainz University
21. Panagiotopoulos T, Ketelsen UP, Schmidt A, Heuck CC (1986) Long-term effect of magnesium pyridoxal-5-phosphate glutamate in rabbits developing hypercholesterolemia. Drug Res 36:1210-1215
22. Walma EP, Grundmeijer HGLM, Thomas S, Prins A, van den Hoogen JPH, van der Laan JR (1997) The DCGP standard on Hypertension [DCGP - Dutch College of General Practitioners] (in Dutch). Huisarts Wet 40:598-617 (translation available: Nederlands Huisartsen Genootschap, Lohmanlaan 103, 2536 XD Utrecht)
23. Van Binsbergen JJ, Brouwer A, Van Drenth BB, Haverkort AFM, Prins A, Van der Weijden T (1991) NHG-Standaard: cholesterol. Huisarts Wet 34:551-557 (translation available: Nederlands Huisartsen Genootschap, Lohmanlaan 103, 2536 XD Utrecht)
24. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR et al (1990) The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 150:1881-1884
25. Avorn J, Monette J, Lacour A, Bohn RL, Monane M, Mogun H et al (1998) Persistence of use of lipid-lowering medications. JAMA 279:1458-1462